Unichem Laboratories logo

Unichem Laboratories CEO, MD, chairman, board of directors and AGM

NSE: UNICHEMLABBSE: 506690Pharmaceuticals & BiotechnologySmall Cap

Last close ₹472.95down ₹14.80 (3.03%)BSE ₹471.95

Share price at the NSE close on 23 Oct 2026. Previous close ₹487.75.

52-week range of traded prices to 23 Oct 2026
₹278.20Low, 30 Mar 2026₹687.20High, 9 Jul 2026
Market cap
₹3,330 Cr1,036th largest listed
P/E
10.9
P/E without one-offs
33.3
P/B
1.2
Dividend yield
Nonein the last 12 months
ROE
11.8%
ROE without one-offs
3.9%
ROCE
3.3%
Debt to equity
0.17
Volume, NSE
40,08440.7% delivered

Unichem Laboratories board of directors

At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares

  • ChairpersonMody Prakash AmrutRelated to the promoter
  • Managing director and CEOPabitrakumar Kalipada Bhattacharyya
  • Company Secretary and Compliance OfficerPradeep Bhandari

6 directors3 independent1 executive2 non-executive

  • Mody Prakash Amrut · ChairpersonNon-executive · joined Jun 1974 · reappointed Aug 2025 · 1 listed board
  • Pranay GodhaNon-executive · joined Aug 2023 · reappointed Aug 2024 · 2 listed boards · 1 committee seat
  • Pabitrakumar Kalipada Bhattacharyya · Managing director and CEOExecutive · joined Aug 2023 · 2 listed boards · 2 committee seats
  • Arun Lalchand TodarwalIndependent · joined Feb 2024 · reappointed Feb 2024 · 28 months as independent · 4 listed boards · 3 as independent · 9 committee seats, 3 as chair
  • Anand Trimbak KurseIndependent · joined Feb 2024 · reappointed Feb 2024 · 28 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
  • Swati Arvind PatankarIndependent · joined Feb 2026 · 4 months as independent · 2 listed boards · 2 as independent · 3 committee seats

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

1 director who left
  • Priti Puri, left 20 Mar 2026: Tenure Completion

Committees and meetings

Who sits on each, and how often they met.Board meeting notices and outcomes

  • Board

    • 22 May 20266 of 6 present3 independent · 76 days in between
    • 6 Mar 20267 of 7 present4 independent · 28 days in between
    • 5 Feb 20265 of 6 present2 independent

  • Audit Committee

    Chair Arun Lalchand Todarwal

    Pabitrakumar Kalipada Bhattacharyya, Anand Trimbak Kurse, Swati Patankar

    • 22 May 20264 of 4 present3 independent · 105 days in between
    • 5 Feb 20263 of 4 present2 independent

  • Nomination and remuneration committee

    Chair Arun Lalchand Todarwal

    Anand Trimbak Kurse, Swati Patankar

    • 22 May 20263 of 3 present3 independent
    • 5 Feb 20262 of 3 present2 independent

  • Stakeholders Relationship Committee

    Chair Anand Trimbak Kurse

    Pranay Godha, Pabitrakumar Kalipada Bhattacharyya, Swati Patankar

    • 22 May 20264 of 4 present2 independent

  • Risk Management Committee

    Chair Arun Lalchand Todarwal

    Pranay Godha, Pabitrakumar Kalipada Bhattacharyya, Anand Trimbak Kurse

    • 5 Feb 20264 of 4 present2 independent

  • Corporate Social Responsibility Committee

    Chair Arun Lalchand Todarwal

    Pranay Godha, Pabitrakumar Kalipada Bhattacharyya

    • 22 May 20263 of 3 present1 independent

Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.

Statutory auditor

Named in the results for the quarter to Mar 2026.

  • N A Shah Associates LLPPeer-review certificate valid to Aug 2028

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

Unichem Laboratories AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Unichem Laboratories dividend history

Annual general meeting, 11 Aug 2026

25,183 shareholders on the register on 4 Aug 2026; present: 2 promoters and 53 others; votes counted by Mr. Alwyn D'Souza / Alwyn Jay & Co.The company's voting result (opens in a new tab)

  1. Consider and adopt the audited standalone financial statements and reports of the directors and auditors thereon for the year ended 31st March 2026.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.03%

    Turnout: all 81.20% · promoters 100.00% · institutions 90.25% · other public 0.28%

  2. Consider and adopt the audited consolidated financial statements and the auditors report for the year ended 31st March 2026.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.03%

    Turnout: all 81.20% · promoters 100.00% · institutions 90.25% · other public 0.28%

  3. To appoint a director in place of Mr. Pabitrakumar Bhattacharyya (DIN: 07131152), who retires by rotation and being eligible has offered himself for re-appointment.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 1.25%

    Turnout: all 81.21% · promoters 100.00% · institutions 90.40% · other public 0.28%

  4. Re-appointment of Mr. Pabitrakumar Bhattacharyya as Managing Director & Chief Executive Officer.
    Special
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 1.25%

    Turnout: all 81.21% · promoters 100.00% · institutions 90.40% · other public 0.28%

  5. Ratification of remuneration of Cost Auditors, Kishore Bhatia & Associates for FY 2027.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.03%

    Turnout: all 81.21% · promoters 100.00% · institutions 90.40% · other public 0.28%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 27 Mar 2026, 3 resolutions

24,132 shareholders on the register on 20 Feb 2026; votes counted by Alwyn D’Souza / Alwyn Jay & Co..The company's voting result (opens in a new tab)

  1. Approval of Appointment of Dr. (Ms) Swati Patankar (DIN 06594600) as a Non-Executive Independent Director for a term of five years w.e.f. 5th February 2026
    Special
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.82%

    Turnout: all 80.55% · promoters 100.00% · institutions 87.46% · other public 0.53%

  2. Approval of Material related party transaction(s) between Ipca, holding company of Unichem and Unichem Pharmaceuticals USA Inc. (“Unichem USA”), wholly owned subsidiary of Unichem
    OrdinaryPromoters have an interest in it
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.82%

    Turnout: all 10.33% · promoters 0.00% · institutions 87.46% · other public 0.53%

  3. Approval of Material related party transaction(s) with Unichem USA, wholly owned subsidiary of Unichem
    OrdinaryPromoters have an interest in it
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.88%

    Turnout: all 10.32% · promoters 0.00% · institutions 87.46% · other public 0.49%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 4 Aug 2025, 7 resolutions

23,569 shareholders on the register on 28 Jul 2025; present: 6 promoters and 64 others; votes counted by Mr. Alwyn D'Souza / Alwyn Jay & Co.The company's voting result (opens in a new tab)

  1. 1a. Consider and adopt the audited standalone financial statements and reports of the directors and auditors thereon for the year ended 31st March 2025. 1b. Consider and adopt the audited consolidated financial statements and the auditors report for the year ended 31st March 2025.MoreLess
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.03%

    Turnout: all 80.46% · promoters 100.00% · institutions 86.77% · other public 0.28%

  2. To appoint a director in place of Mr. Prakash Mody (DIN: 00001285) who retires by rotation and being eligible has offered himself for re-appointment.
    Ordinary
    99.21% for0.79% against

    Against: promoters 0.00% · institutions 6.22% · other public 0.06%

    Turnout: all 80.47% · promoters 100.00% · institutions 86.93% · other public 0.28%

  3. Material Related party transaction(s) with holding company, Ipca Laboratories Limited
    OrdinaryPromoters have an interest in it
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.01% · other public 0.18%

    Turnout: all 10.25% · promoters 0.00% · institutions 86.93% · other public 0.26%

  4. Material Related party transaction(s) between holding company, Ipca Laboratories Limited and wholly owned subsidiary, Unichem Pharmaceuticals (USA) Inc.
    OrdinaryPromoters have an interest in it
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.01% · other public 0.18%

    Turnout: all 10.25% · promoters 0.00% · institutions 86.93% · other public 0.26%

  5. Material Related party transaction(s) with wholly owned subsidiary, Unichem Pharmaceuticals (USA) Inc.
    OrdinaryPromoters have an interest in it
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.01% · other public 0.18%

    Turnout: all 10.25% · promoters 0.00% · institutions 86.93% · other public 0.26%

  6. Appointment of Ms. Alwyn Jay and Co., Secretarial Auditors for a period of five consecutive years from 1st April 2025 to 31st March 2030.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.06%

    Turnout: all 80.47% · promoters 100.00% · institutions 86.93% · other public 0.28%

  7. Ratification of remuneration payable to the Cost Auditors, Kishore Bhatia & Associates (Firm Registration No. 00294) for the year ended 31st March, 2026.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.03%

    Turnout: all 80.47% · promoters 100.00% · institutions 86.93% · other public 0.28%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 8 Aug 2024, 3 resolutions

Present: 5 promoters and 74 others.The company's voting result (opens in a new tab)

  1. 1a. Consider and adopt the audited standalone financial statements and reports of the directors and auditors thereon for the year ended 31st March 2024.n1b. Consider and adopt the audited consolidated financial statements and the auditors report for the year ended 31st March 2024MoreLess
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.24%

    Turnout: all 81.41% · promoters 100.00% · institutions 88.99% · other public 0.19%

  2. To appoint a director in place of Mr. Pranay Godha (DIN: 00016525) who retires by rotation and being eligible has offered himself for re-appointment.
    Ordinary
    98.24% for1.76% against

    Against: promoters 0.00% · institutions 12.79% · other public 0.33%

    Turnout: all 81.43% · promoters 100.00% · institutions 89.13% · other public 0.19%

  3. Ratification of remuneration payable to the Cost Auditors, Kishore Bhatia & Associates (Firm Registration No. 00294) for the year ended 31st March, 2025
    Ordinary
    98.24% for1.76% against

    Against: promoters 0.00% · institutions 12.79% · other public 0.33%

    Turnout: all 81.43% · promoters 100.00% · institutions 89.13% · other public 0.19%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 22 Mar 2024, 5 resolutions

The company's voting result (opens in a new tab)

  1. Appointment of Mr. Anand Kusre (DIN 00818477) as a Non-Executive Independent Director for a term of five years.
    Special
    96.79% for3.21% against

    Against: promoters 0.00% · institutions 24.42% · other public 0.20%

    Turnout: all 80.91% · promoters 100.00% · institutions 88.29% · other public 0.29%

  2. Appointment of Mr. Arun Todatwal (DIN 00020916) as a Non-Executive Independent Director for a term of five years.
    Special
    98.66% for1.34% against

    Against: promoters 0.00% · institutions 10.19% · other public 0.27%

    Turnout: all 80.91% · promoters 100.00% · institutions 88.29% · other public 0.29%

  3. Material Related party transaction(s) with Ipca Laboratories Limited.
    OrdinaryPromoters have an interest in it
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.26%

    Turnout: all 10.62% · promoters 0.00% · institutions 87.70% · other public 0.29%

  4. Material Related party transaction(s) between lpca Laboratories Limited and Unichem Pharmaceuticals (USA) Inc.
    OrdinaryPromoters have an interest in it
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.19%

    Turnout: all 10.62% · promoters 0.00% · institutions 87.70% · other public 0.29%

  5. Material Related party transaction(s) with Unichem Pharmaceuticals (USA) Inc.
    OrdinaryPromoters have an interest in it
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.26%

    Turnout: all 10.62% · promoters 0.00% · institutions 87.70% · other public 0.29%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 25 Sep 2023, 8 resolutions

Present: 2 promoters and 43 others.The company's voting result (opens in a new tab)

  1. Consider and adopt the audited standalone financial statements and reports of the directors and auditors thereon for the year ended 31st March, 2023.n
    Ordinary
    97.82% for2.18% against

    Against: promoters 0.00% · institutions 13.08% · other public 0.83%

    Turnout: all 61.14% · promoters 99.63% · institutions 68.72% · other public 0.61%

  2. Consider and adopt the audited consolidated financial statements and the auditors report for the year ended 31st March, 2023
    Ordinary
    97.82% for2.18% against

    Against: promoters 0.00% · institutions 13.08% · other public 0.83%

    Turnout: all 61.14% · promoters 99.63% · institutions 68.72% · other public 0.61%

  3. To appoint a director in place of Dr. Prakash A. Mody (DIN: 00001285), who retires by rotation and being eligible has offered himself for re-appointment.
    Ordinary
    97.82% for2.18% against

    Against: promoters 0.00% · institutions 13.04% · other public 1.19%

    Turnout: all 61.16% · promoters 99.63% · institutions 68.91% · other public 0.61%

  4. Re-designation of Dr. Prakash A. Mody (DIN: 00001285), as the Chairman of the Company in the capacity of Non-Executive, Non- Independent Director, liable to retire by rotation.
    Ordinary
    97.82% for2.18% against

    Against: promoters 0.00% · institutions 13.02% · other public 1.25%

    Turnout: all 61.16% · promoters 99.63% · institutions 68.91% · other public 0.61%

  5. Appointment of Mr. Pranay Godha (DIN:00016525) as the Non-Executive, Non-Independent Director of the Company, liable to retire by rotation.
    Ordinary
    97.82% for2.18% against

    Against: promoters 0.00% · institutions 13.04% · other public 1.20%

    Turnout: all 61.16% · promoters 99.63% · institutions 68.91% · other public 0.61%

  6. Appointment of Mr. Pabitrakumar Kalipada Bhattacharyya (DIN:07131152) as a Director of the Company, liable to retire by rotation.
    Ordinary
    97.94% for2.06% against

    Against: promoters 0.00% · institutions 12.33% · other public 1.18%

    Turnout: all 61.16% · promoters 99.63% · institutions 68.91% · other public 0.61%

  7. Appointment of Mr. Pabitrakumar Kalipada Bhattacharyya (DIN:07131152) as the Managing Director of the Company, liable to retire by rotation.
    Special
    99.20% for0.80% against

    Against: promoters 0.00% · institutions 4.75% · other public 1.18%

    Turnout: all 61.16% · promoters 99.63% · institutions 68.91% · other public 0.61%

  8. Ratification of remuneration payable to the Cost Auditors, Kishore Bhatia & Associates (Firm Registration No. 00294)for the year ended 31st March, 2024.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 1.18%

    Turnout: all 61.16% · promoters 99.63% · institutions 68.91% · other public 0.61%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 3 May 2023, 1 resolution

The company's voting result (opens in a new tab)

  1. Appointment of Mrs. Priti Puri (DIN: 07755966) as a Non-Executive Independent Director of the Company for a term of three (3) years w.e.f. March 21, 2023.
    Special
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.38%

    Turnout: all 61.73% · promoters 100.00% · institutions 91.04% · other public 4.64%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 9 Aug 2022, 6 resolutions

Present: 1 promoter and 51 others.The company's voting result (opens in a new tab)

  1. To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended 31st March, 2022 and the reports thereon.
    Ordinary
    96.57% for3.43% against

    Against: promoters 0.00% · institutions 22.75% · other public 0.22%

    Turnout: all 61.62% · promoters 100.00% · institutions 83.81% · other public 3.73%

  2. To receive, consider and adopt the audited consolidated financial statements of the Company for the financial year ended 31st March, 2022 and the reports of the auditors thereon.
    Ordinary
    96.57% for3.43% against

    Against: promoters 0.00% · institutions 22.75% · other public 0.22%

    Turnout: all 61.62% · promoters 100.00% · institutions 83.81% · other public 3.73%

  3. To declare a Dividend of Rs. 4/- (200%) per equity share for the financial year ended 31st March, 2022
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.05%

    Turnout: all 61.64% · promoters 100.00% · institutions 84.07% · other public 3.73%

  4. To appoint a Director in place of Mr. Dilip Kunkolienkar (DIN: 02666678) who retires by rotation and, being eligible, offers himself for re-appointment
    Ordinary
    98.04% for1.96% against

    Against: promoters 0.00% · institutions 12.95% · other public 0.41%

    Turnout: all 61.64% · promoters 100.00% · institutions 84.07% · other public 3.73%

  5. Re-appointed as Statutory Auditors of the Company for a second term of 5 (five) consecutive years.
    Ordinary
    98.03% for1.97% against

    Against: promoters 0.00% · institutions 13.05% · other public 0.32%

    Turnout: all 61.64% · promoters 100.00% · institutions 84.07% · other public 3.73%

  6. Appointment Cost Auditor conducting Cost Audit of the records maintained by the Company for the financial year ending 31st March, 2023, be and is hereby ratified
    Ordinary
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.23%

    Turnout: all 61.64% · promoters 100.00% · institutions 84.07% · other public 3.73%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

How mutual funds voted

Fund houses must disclose how they vote at every meeting of a company they hold.

Mutual fund votes, meeting of 11 Aug 2026, 1 fund house so far (houses' deadline to file 15 Oct 2026)

  • Consider and adopt the audited standalone financial statements and reports of the directors and auditors thereon for the year ended 31st March 2026.
    1 for0 against
  • Consider and adopt the audited consolidated financial statements and the auditors report for the year ended 31st March 2026.
    1 for0 against
  • To appoint a director in place of Mr. Pabitrakumar Bhattacharyya (DIN: 07131152), who retires by rotation and being eligible has offered himself for re-appointment.
    1 for0 against
  • Re-appointment of Mr. Pabitrakumar Bhattacharyya as Managing Director & Chief Executive Officer.
    1 for0 against
  • Ratification of remuneration of Cost Auditors, Kishore Bhatia & Associates for FY 2027.
    1 for0 against

Mutual fund votes, meeting of 27 Mar 2026, 4 fund houses

  • Approval of Appointment of Dr. (Ms) Swati Patankar (DIN 06594600) as a Non-Executive Independent Director for a term of five years w.e.f. 5th February 2026
    4 for0 against
  • Approval of Material related party transaction(s) between Ipca, holding company of Unichem and Unichem Pharmaceuticals USA Inc. (“Unichem USA”), wholly owned subsidiary of Unichem
    4 for0 against
  • Approval of Material related party transaction(s) with Unichem USA, wholly owned subsidiary of Unichem
    4 for0 against
6 earlier meetings

Mutual fund votes, meeting of 4 Aug 2025, 4 fund houses

  • 1a. Consider and adopt the audited standalone financial statements and reports of the directors and auditors thereon for the year ended 31st March 2025. 1b. Consider and adopt the audited consolidated financial statements and the auditors report for the year ended 31st March 2025.MoreLess
    4 for0 against
  • To appoint a director in place of Mr. Prakash Mody (DIN: 00001285) who retires by rotation and being eligible has offered himself for re-appointment.
    4 for0 against
  • Material Related party transaction(s) with holding company, Ipca Laboratories Limited
    Against Bandhan Mutual Fund, Motilal Oswal Mutual Fund
    • Bandhan Mutual Fund, Motilal Oswal Mutual FundCompliant with Law. Transparency and Governance Concern: Unclear how the sale or purchase of Assets fall within the ordinary course of business. No adequate disclosures on fairness of pricing for extension or availing of loans / advances / guarantees.
    2 for2 against
  • Material Related party transaction(s) between holding company, Ipca Laboratories Limited and wholly owned subsidiary, Unichem Pharmaceuticals (USA) Inc.
    Against Bandhan Mutual Fund, Motilal Oswal Mutual Fund
    • Bandhan Mutual Fund, Motilal Oswal Mutual FundCompliant with Law. Transparency and Governance Concern: Unclear how the sale or purchase of Assets fall within the ordinary course of business. No adequate disclosures on fairness of pricing for extension or availing of loans / advances / guarantees.
    2 for2 against
  • Material Related party transaction(s) with wholly owned subsidiary, Unichem Pharmaceuticals (USA) Inc.
    Against Bandhan Mutual Fund, Motilal Oswal Mutual Fund
    • Bandhan Mutual Fund, Motilal Oswal Mutual FundCompliant with Law. Transparency and Governance Concern: Unclear how the sale or purchase of Assets fall within the ordinary course of business. No adequate disclosures on fairness of pricing for extension or availing of loans / advances / guarantees.
    2 for2 against
  • Appointment of Ms. Alwyn Jay and Co., Secretarial Auditors for a period of five consecutive years from 1st April 2025 to 31st March 2030.
    4 for0 against
  • Ratification of remuneration payable to the Cost Auditors, Kishore Bhatia & Associates (Firm Registration No. 00294) for the year ended 31st March, 2026.
    3 for0 against

Mutual fund votes, meeting of 8 Aug 2024, 5 fund houses

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

  • 1a. Consider and adopt the audited standalone financial statements and reports of the directors and auditors thereon for the year ended 31st March 2024.n1b. Consider and adopt the audited consolidated financial statements and the auditors report for the year ended 31st March 2024MoreLess
    4 for0 against
  • To appoint a director in place of Mr. Pranay Godha (DIN: 00016525) who retires by rotation and being eligible has offered himself for re-appointment.
    Against Franklin Templeton Mutual Fund
    • Franklin Templeton Mutual FundA vote AGAINST the following nominee is warranted because the board is chaired by a promoter director and the board is not at least one-half independent and Pranay Premchand Godha is a non-independent director nominee.
    4 for1 against
  • Ratification of remuneration payable to the Cost Auditors, Kishore Bhatia & Associates (Firm Registration No. 00294) for the year ended 31st March, 2025
    4 for0 against
3 proposals not matched to one resolution
  • Accept Consolidated Financial Statements and Statutory Reports
    1 for0 against
  • Accept Standalone Financial Statements and Statutory Reports
    1 for0 against
  • Approve Remuneration of Cost Auditors
    1 for0 against

Mutual fund votes, meeting of 22 Mar 2024, 5 fund houses

  • Appointment of Mr. Anand Kusre (DIN 00818477) as a Non-Executive Independent Director for a term of five years.
    Against DSP Mutual Fund, Franklin Templeton Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund
    • DSP Mutual FundAnand Kusre, 74, was associated with ICICI Bank for 25 years and held leadership roles in project finance, operations, technology development and commercialization programs, etc. He subsequently joined IIT Bombay where he designed and taught courses in innovation, entrepreneurship and management of technology. In 2015, he founded the Desai Sethi School of Entrepreneurship at IIT Bombay. Ipca Laboratories (Ipca) acquired 52.7% equity in Unichem Laboratories in FY24. He has been an Independent Director on the board of Ipca (holding company) since 21 January 2010 and thus his overall association with the promoter group (Godha family) and holding company exceeds ten years. We believe that the length of tenure is inversely proportionate to the independence of a director. Therefore, we consider him as non-independent due to his long association (>10 years) with the group. The company must consider appointing him as Non-Executive Non-Independent Director. He will attain the age of 75 in July 2024. We do not consider age to be a criterion for board memberships. Given his long association with the group, we are unable to support his appointment.
    • Franklin Templeton Mutual FundA vote AGAINST election of Anand Kusre and continuation post attaining age of 75 years is warranted because his current appointment will exceed his association with the company (including holding company) for more than ten years thus, affecting his independence.
    • Groww Mutual FundCompliant with law. Governance concern: Prolonged association.
    • Motilal Oswal Mutual Fund"Non-Compliant with SEBI (LODR) & Companies Act, 2013: Terms and Conditions of the Independent Directors not disclosed on the website. Governance concern: Prolonged association."
    1 for4 against
  • Appointment of Mr. Arun Todatwal (DIN 00020916) as a Non-Executive Independent Director for a term of five years.
    Against DSP Mutual Fund, Motilal Oswal Mutual Fund
    • DSP Mutual FundArun Todarwal, 66, is a practicing Chartered Accountant and Managing Partner of Arun Todarwal & Associates LLP. He has over 40 years of experience in management consultancy, statutory audit, internal audit, management and system audit, due diligence, taxation, international taxation etc. While his appointment is in line with statutory requirements, we are unable to support the resolution. Arun Todarwal serves on the board of four listed companies (including Unichem Laboratories Ltd.). Given their full-time responsibilities, regulations allow whole-time directors of listed companies to be independent directors in a maximum of three listed companies. We believe that as the Partner of Arun Todarwal & Associates LLP, his responsibilities are equivalent to a whole-time directorship of a listed company. Therefore, his high number of directorships on listed companies is not in keeping with the spirit of the regulation. We do not support his appointment as Independent Director.
    • Motilal Oswal Mutual FundNon-Compliant with SEBI (LODR) & Companies Act, 2013: Terms and Conditions of the Independent Directors not disclosed on the website.
    3 for2 against
  • Material Related party transaction(s) with Ipca Laboratories Limited.
    5 for0 against
  • Material Related party transaction(s) between lpca Laboratories Limited and Unichem Pharmaceuticals (USA) Inc.
    5 for0 against
  • Material Related party transaction(s) with Unichem Pharmaceuticals (USA) Inc.
    5 for0 against

Mutual fund votes, meeting of 25 Sep 2023, 2 fund houses

  • Consider and adopt the audited standalone financial statements and reports of the directors and auditors thereon for the year ended 31st March, 2023.n
    Against Motilal Oswal Mutual Fund
    • Motilal Oswal Mutual FundQualified opinion on Standalone and Consolidated financial statements.
    1 for1 against
  • Consider and adopt the audited consolidated financial statements and the auditors report for the year ended 31st March, 2023
    Against Motilal Oswal Mutual Fund
    • Motilal Oswal Mutual FundQualified opinion on Standalone and Consolidated financial statements.
    1 for1 against
  • To appoint a director in place of Dr. Prakash A. Mody (DIN: 00001285), who retires by rotation and being eligible has offered himself for re-appointment.
    2 for0 against
  • Re-designation of Dr. Prakash A. Mody (DIN: 00001285), as the Chairman of the Company in the capacity of Non-Executive, Non- Independent Director, liable to retire by rotation.
    2 for0 against
  • Appointment of Mr. Pranay Godha (DIN:00016525) as the Non-Executive, Non-Independent Director of the Company, liable to retire by rotation.
    2 for0 against
  • Appointment of Mr. Pabitrakumar Kalipada Bhattacharyya (DIN:07131152) as a Director of the Company, liable to retire by rotation.
    Against Motilal Oswal Mutual Fund
    • Motilal Oswal Mutual FundCompliant with law. Governance concern: No absolute cap on variable pay.
    1 for1 against
  • Appointment of Mr. Pabitrakumar Kalipada Bhattacharyya (DIN:07131152) as the Managing Director of the Company, liable to retire by rotation.
    Against Motilal Oswal Mutual Fund
    • Motilal Oswal Mutual FundCompliant with law. Governance concern: No absolute cap on variable pay.
    1 for1 against
  • Ratification of remuneration payable to the Cost Auditors, Kishore Bhatia & Associates (Firm Registration No. 00294)for the year ended 31st March, 2024.
    2 for0 against

Mutual fund votes, meeting of 3 May 2023, 2 fund houses

  • Appointment of Mrs. Priti Puri (DIN: 07755966) as a Non-Executive Independent Director of the Company for a term of three (3) years w.e.f. March 21, 2023.
    2 for0 against

Mutual fund votes, meeting of 9 Aug 2022, 2 fund houses

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

  • To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended 31st March, 2022 and the reports thereon.
    2 for0 against
  • To receive, consider and adopt the audited consolidated financial statements of the Company for the financial year ended 31st March, 2022 and the reports of the auditors thereon.
    2 for0 against
  • To declare a Dividend of Rs. 4/- (200%) per equity share for the financial year ended 31st March, 2022
    2 for0 against
  • To appoint a Director in place of Mr. Dilip Kunkolienkar (DIN: 02666678) who retires by rotation and, being eligible, offers himself for re-appointment
    2 for0 against
  • Re-appointed as Statutory Auditors of the Company for a second term of 5 (five) consecutive years.
    2 for0 against
1 proposal not matched to one resolution
  • Ratification of remuneration of not exceeding Rs. 9.00 lakhs (Rupees Nine Lakhs Only) plus applicable taxes and reimbursement of out-of-pocket expenses as approved by the Board of Directors of the Company payable to Kishore Bhatia & Associates, Cost Accountants, (Firm Registration No. 00294) for conducting Cost Audit of the records maintained by the Company for the financial year ending 31st March, 2023.MoreLess
    2 for0 against

Each fund house counted once, from its own disclosure; the reasons are its own words.

Tax disputes

Reported in the filing for the quarter to Jun 2026.

  • Tax disputeJoint Commissioner CGST & CX, Thane CommissionerateSince 20 Mar 2025
    Appeal filed, pending for hearing
    At the filing before: Assessment dated 14th January 2025, issued for interest of Rs 6,58,76,590 and penalty of Rs. 87,07,09,556/-
  • Tax disputeAsst. Commissioner Central Goods and Service Tax Division DehradunSince 26 Mar 2025
    Appeal heard on 4th November, 2025. Order awaited.
    At the filing before: Order issued for disallowance of TRAN 1 credit of Rs 73,02,757 u/s 140(3) of the CGST Act, 2017 and penalty u/s 74 & 122 of CGST Act, Rs. 73,02,757/-

In the company's own words, from its latest governance filing.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

  • Received
  • Resolved

Open at the quarter's end

None open at any quarter's end.
The board is made up as the listing rules require
Yes
The board has a regular chairperson
Yes
The company has a risk management committee
Yes
The chair is related to the managing director
No
The filing has a part on fines and penalties
No
The filing has a part on tax disputes
Yes
There was a cyber security incident in the quarter
No

The company's own answers in its filing.